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Objective: To test the hypothesis that low serum folate concentrations are associated with an increased risk of
acute coronary events in men free of prior coronary heart disease.
Setting: Research Institute of Public Health, University of Kuopio, Kuopio, Finland.
Design: Prospective study in a cohort of 734 men aged 46 ± 64 y examined in 1991 ± 1993 as part of the Kuopio
Ischaemic Heart Disease Risk Factor Study (KIHD) and followed for 5 y and 3 months.
Intervention: Acute coronary events during the follow-up period were obtained by national hospital discharge
registry. Baseline serum folate concentrations were measured by radioimmunoassay.
Results: During the follow-up, six (2.5%) men with higher serum folate concentrations (highest third
>11.3 nmol=1) and 28 (5.7%) men with lower serum folate (two lowest thirds) developed an acute coronary
event (P 0.008). In a Cox model adjusting for age, examination years, and plasma lycopene concentration, in
men with higher serum folate concentrations the relative risk for an acute coronary event was 0.31 (95% CI
0.11 ± 0.90, P 0.031) when compared with men with lower serum folates.
Conclusion: This prospective cohort study in middle-aged men from eastern Finland indicates that moderate-to-
high levels of serum folate are associated with a greatly reduced incidence of acute coronary events.
Descriptors: myocardial infarction; acute coronary event, folate; homocysteine; cohort studies; prospective
studies; Finland
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Introduction
A number of cross-sectional studies have noted higher
concentrations of plasma total homocysteine (tHcy) in
patients with cardiovascular disease (CVD) as compared
with controls, suggesting that elevated plasma tHcy con-
centration is a risk factor for cardiovascular disease CVD
(Boushey et al, 1995; Refsum et al, 1998). This association
has been con®rmed in some, but not in all prospective
studies (Stampfer et al, 1992; Verhoef et al, 1994; Perry
et al, 1995; Arnesen et al, 1995; Folsom et al, 1998; Wald
et al, 1998; Alfthan et al, 1994; Evans et al, 1997). In a
cross-country study with WHO MONICA data (Alfthan
et al, 1997) high plasma tHcy concentrations were asso-
ciated with increased cardiovascular mortality, and both the
mean plasma tHcy concentration and cardiovascular mor-
tality were the highest in Finland. Plasma tHcy concentra-
tions may be elevated due to de®ciencies of enzyme
activities in homocysteine metabolism or de®ciencies of
folic acid, vitamin B6 or B12. Approximately two-thirds of
the cases of elevated tHcy have been estimated to be due to
low or moderate concentrations of these vitamins (Selhub
et al, 1993), of which folic acid is considered the most
important (Ubbrink et al, 1994).
Few previous epidemiological studies have addressed
the link between folate and the risk of CVD (Verhoef et al,
1998). In these studies, subjects with lower circulating
folate concentrations or lower dietary intake of folic acid
have had a higher risk of coronary events compared with
others, although all studies have not found this association.
In a recent European multi-center case ± control study
(Robinson et al, 1998) with 750 cases and 800 controls,
low circulating concentrations of folate and vitamin B6
conferred an increased risk of atherosclerosis.
Although it has been supposed that elevated plasma
tHcy concentration is an independent risk factor for
CVD, the risk-increasing mechanisms are still poorly
understood. It has been proposed that it alters the anti-
coagulant properties of endothelial cells to a procoagulant
phenotype, causes dysfunction of the vascular endothelium
or enhances lipid peroxidation (Jacobsen, et al 1998).
Although folic acid could lower the risk of CVD through
reducing plasma tHcy concentrations, elevated homocys-
teine may also be only a marker for low folate and vitamin
B6 status rather than a causal risk factor.
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The purpose of this prospective study was to test the
hypothesis that low serum folate concentrations are asso-
ciated with an increased risk of acute coronary events in
men free of prior coronary heart disease (CHD).
Methods
Subjects
The Kuopio Ischaemic Heart Disease Risk Factor Study
(KIHD) is an ongoing prospective population-based cohort
study designed to investigate risk factors for CVD, athero-
sclerosis and related outcomes in middle-aged men from
eastern Finland (Salonen, 1988), the population with one
of the highest recorded rates of CHD. A total of 2682
participants (82.9% those eligible), aged 42, 48, 54 or 60 y,
were enrolled in the study between 1984 and 1989. The
baseline examination for the present prospective cohort
study was carried out during 1991 ± 1993. These examina-
tions were at the same time the 4 y follow-up survey of the
KIHD cohort. Out of a total of 1229 men eligible for the
study, 52 had died, suffered severe illness, or had migrated
from the region, and 139 could not be contacted or refused
to participate. Thus, 1038 men were examined in 1991 ±
1993. As previous disease affects the diet, men with
prevalent CHD (n 298) were excluded from the present
analyses. Of the remaining 740 men, data on serum folate
concentration were available for 734 men.
Measurements
The subjects came to gave venous blood samples between 8
and 10 a.m. in the morning. They were instructed to abstain
from ingesting alcohol for 3 days and from smoking and
eating for 12 h. After the subject had rested in supine
position for 30 min, blood samples were obtained by
venipuncture and collected into vacuum tubes (Venoject;
Terumo, Leuven, Belgium). No tourniquet was used. Blood
for folate and cholesterol determination and for lipoprotein
separation was drawn into serum tubes and blood for a-
tocopherol, lycopene, b-carotene and retinol measurements
was collected in tubes containing lithium and heparin.
Serum folate concentrations were measured by radio-
immunoassay (Quantaphase II, Bio-Rad, Hercules, Califor-
nia, USA). Folate measurements were carried out in 1998
in serum samples collected during 1991 ± 1993 and kept
frozen at ÿ80C. The between-batch coef®cients of varia-
tion (CV) of quality control serum (Lyphochek Immuno-
assay Plus Control levels 1, 2, 3, Bio Rad Laboratories,
ECS Division, Anaheim, California, USA) levels of 5.5,
13.4 and 23.6 nmol=l were 6.4, 6.7 and 6.7%, respectively
(n 16).
Heparin plasma for lycopene, a-tocopherol, b-carotene
and retinol determinations was stored at ÿ80C until
extracted with ethanol and hexane and measured by
HPLC using alpha-tocopherol acetate as an internal stan-
dard (Porkkala-Sarataho et al, 1998). Lipoproteins were
Table 1 Characteristics of the study populationa
Subjects who developed







Serum folate (nmol=l) 9.37 4.07 10.47 3.92 0.101 10.42 3.93
Age (y) 57.7 6.3 55.0 6.6 0.018 55.1 6.6
Body mass index (kg=m2) 27.7 3.2 27.4 3.6 0.699 27.4 3.6
Systolic blood pressure (mmHg) 139.6 14.9 134.7 16.5 0.091 135.0 16.5
Serum total cholesterol (mmol=l) 5.70 0.83 5.49 0.92 0.192 5.50 0.91
Serum LDL cholesterol (mmol=l) 4.13 0.76 3.90 0.81 0.105 3.91 0.81
Serum HDL cholesterol (mmol=l) 1.07 0.31 1.12 0.28 0.343 1.12 0.29
Serum triglycerides (mmol=l) 1.72 0.99 1.55 0.97 0.308 1.56 0.97
Serum lycopene (mmol=l) 0.11 0.12 0.17 0.14 0.019 0.17 0.14
Serum retinol (mmol=l) 2.02 0.41 2.13 0.44 0.166 2.12 0.44
Serum a-tocopherol (mmol=l) 29.66 7.55 28.49 7.65 0.384 28.54 7.64
Smoking (%) 35.3 48.5 26.7 44.2 0.268 27.0 44.4
a x s.d.; statistical analyses were based on one-way ANOVA.
Table 2 Characteristics of the study subjects in the two lowest thirds and in the highest third of baseline serum folate
concentrationa
Serum folate concentration (nmol=l)
 11.3 >11.3 P for
(n 493) (n 241) difference
Serum folate (nmol=l) 8.3 14.7
Age (y) 55.6 54.1 0.004
Body mass index (kg=m2) 27.2 28.0 0.005
Systolic blood pressure (mmHg) 134.3 136.3 0.116
Serum triglycerides (mmol=l) 1.49 1.70 0.006
Serum LDL cholesterol (mmol=l) 3.91 3.90 0.845
Serum HDL cholesterol (mmol=l) 1.11 1.14 0.173
Smoking (%) 28.3 24.6 0.294
Serum retinol (mmol=l) 2.05 2.26 < 0.001
Serum a-tocopherol (mmol=l) 27.7 30.3 < 0.001
Serum lycopene (mmol=l) 0.15 0.20 < 0.001
Serum beta-carotene (mmol=l) 0.41 0.40 0.881
Number of subjects who developed an acute coronary event (%) 28 [5.7] 6 [2.5] 0.008
a x percentage in brackets. Statistical analyses were based on one-way ANOVA.
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separated from fresh serum samples by combined ultra-
sentrifugation and precipitation (Salonen et al, 1995).
Serum total, LDL and HDL cholesterol (Kone Instruments,
Espoo, Finland) and triglyceride (Boehringer Mannheim,
Mannheim, Germany) concentrations were determined
enzymatically with an autoanalyser (Kone Speci®c, Kone
Instruments, Finland).
Resting blood pressure was measured by two trained
nurses with random-zero mercury sphygmomanometer
(Hawksley, UK). The measuring protocol included, after
supine rest of 5 min, three measurements in supine, one on
standing and two in sitting position with 5 min intervals.
The mean of all six measurements was used as the systolic
and diastolic blood pressure.
Dietary intake of folic acid was assessed with a 4 day
food recording at the KIHD baseline examinations. Intake
of nutrients was estimated using NUTRICA1 software.
The data bank of NURTICA1 is compiled using mainly
Finnish values of nutrient composition of foods.
Ascertainment of follow-up events
The province of Kuopio participated in the multinational
MONICA (Monitoring of Trends and Determinants of
Cardiovascular Disease) project (Tuomilehto et al, 1992),
in which detailed diagnostic information of all heart attacks
that occurred by December 1992 was collected prospec-
tively. The diagnostic classi®cation was made by the
FINMONICA coronary registry group (Salonen, 1988).
Data on acute coronary events between January 1993 and
December 1997 were obtained by computer linkage to the
national hospital discharge register and classi®ed by one
internist (TAL) using identical diagnostic criteria, includ-
ing symptoms, cardiac enzymes and electrocardiographic
®ndings, as explained previously (Tuomilehto et al, 1992).
The average follow-up time was 5 y and 3 months. If
multiple non-fatal events occurred during the follow-up,
the ®rst event for each subject was considered as end point
for the analyses. According to the diagnostic classi®cation
of the events there were 20 de®nite and 10 possible acute
myocardial infarctions (AMI), and 4 typical prolonged
chest pain episodes.
Statistical methods
The data are expressed as means s.d. Means were com-
pared by analysis of variance (ANOVA). The subjects were
classi®ed into thirds according to their serum folate con-
centration. The relationship of serum folate to the risk of
acute coronary events was analysed using Cox proportional
hazard models. Risk factor adjusted relative hazards (risks),
adjusted for other risk factors, were estimated as the
antilogarithms of coef®cients from multivariate models.
The con®dence intervals were estimated on the basis of
the assumption of asymptotic normality of the estimates.
All tests of signi®cance were two-sided.
Results
The baseline characteristics of the study cohort, separately
for cohort members who developed an acute coronary event
and subjects who did not are shown in Table 1. The mean
age of the study men was 55.1 ( 6.6) y. Subjects who
developed an acute coronary event were older (P 0.018)
and had lower serum lycopene concentration (P 0.019)
than other subjects. The mean serum folate concentration
was 10.4 nmol=l (2.3 ± 38.7 nmol=l) in the study cohort.
Serum folate concentration was 10.5% lower in subjects
who developed an acute coronary event than in those who
did not.
We compared men in the highest third of serum folate
concentration (>11.3 nmol=l) to those with lower serum
folate concentrations. Men with higher serum folate con-
centration differed statistically signi®cantly from men with
lower folate concentrations with regard to age, serum
triglycerides, body mass index, and with regard to nutri-
tional factors including serum lycopene, serum retinol, and
serum alpha-tocopherol (Table 2). During the follow-up
time of 5 years and 3 months, six (2.5%) men with higher
serum folate concentrations (highest third >11.3 nmol=l)
and 28 (5.7%) men with lower serum folate (two lowest
thirds) developed an acute coronary event (P 0.008)
(Table 2). In a Cox proportional hazard model adjusting
for age, examination years, and plasma lycopene concen-
tration, in men with higher serum folate concentrations the
relative risk for acute coronary event was 0.31 (95% CI
0.11 ± 0.90, P 0.031) when compared with men with
lower serum folates. In a Cox model including examination
years, age, and traditional CVD risk factors (smoking,
systolic blood pressure, serum LDL and HDL cholesterol),
the relative risk for those with higher serum folates
remained almost identical (0.30, 95% CI 0.10 ± 0.84,
P 0.023).
Discussion
This prospective cohort study in middle-aged men from
eastern Finland indicates that moderate-to-high concentra-
tions of serum folate are associated with greatly reduced
incidence of acute coronary events. The association is
strong and adjustment for other dietary factors or traditional
CVD risk factors did not attenuate the observed association.
There are a few limitations in this study. First, we have
no plasma tHcy data available. In a prospective Physician's
Health Study (Chasan-Taber et al, 1996), after adjusting for
six other risk factors men in the lowest plasma folate ®fths
had an increased risk of myocardial infarction (MI) com-
pared with those with higher concentrations. After adding
plasma tHcy in the model, the relative risk remained
unchanged. The authors suggested that the increased risk
for MI may be partly independent of homocysteine eleva-
tion. Because plasma tHcy data were not available, we
could not examine whether plasma tHcy levels could
explain any of the association between serum folate con-
centration and acute coronary events. Secondly, we cannot
fully exclude the possibility that part of the association may
re¯ect confounding by other dietary and lifestyle factors
associated with a reduced risk of CHD. In the Finnish diet,
folic acid is found mostly in foodstuffs of plant origin
(National Public Health Institute: Nutrition Report, 1998),
and other nutrients such as carotenoids or ¯avonoids may
contribute to the apparent bene®t. However, scrum con-
centrations of lycopene, vitamin A and E, also markers of
healthy diet, did not confound this association in our study
cohort. Finally, our follow-up period is quite short (5.25 y)
and we have a very limited number of events, so we could
not study the association in possibly relevant subgroups.
An association between dietary intake of folic acid or
circulating folate concentration and CVD has been studied
earlier in several studies (Chasan-Taber et al, 1996; Morri-
son et al, 1996; Rimm et al 1988; Folsom et al, 1998; Giles
et al, 1995, 1998). In the prospective Physician's Health
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Study (Chasan-Taber et al, 1996), men with the lowest 20%
of plasma folate concentrations had a 1.4 fold (95% CI
0.9 ± 2.3) relative risk compared with those in the top 80%,
adjusting for common cardiovascular risk factors. Although
the results were not statistically signi®cant, the authors
concluded that low dietary intake of folic acid contributes
to the risk of MI. In the Nutrition Canada Survey cohort
study (Morrison et al, 1996), low serum folate concentra-
tions were associated with an increased 15-y CHD mortal-
ity among both men and women. Increased risks were not
restricted to individuals with extremely low serum folate
concentrations, but were observed for individuals with
normal concentrations as well. In the Nurses' Health
Study (Rimm et al, 1988) after controlling for cardiovas-
cular risk factors, the relative risk of CHD comparing the
extreme folic acid intake ®fths was 0.69 (95% CI 0.55 ±
0.87). The authors also found the strongest apparent bene®t
of a high-folate diet among women who consumed alcohol.
In the Atherosclerosis Risk in Communities Study, neither
plasma folate concentration nor folic acid dietary intake
had an association with CHD (Folsom et al, 1998). In the
prospective First National Health and Nutrition Examina-
tion Survey Epidemiologic Follow-Up Study (Giles et al,
1998), the relative risk of CHD was the greatest for persons
in the lowest serum folate quarter among persons aged 35 ±
55 y, whereas among persons over 55 y the relative risk for
CHD was the greatest in persons in the highest serum folate
quarter. In a recent European multi-center case-control
study (Robinson et al, 1998) with 750 cases and 800 control
subjects, low circulating concentrations of folate and vita-
min B6 conferred an increased risk of atherosclerosis. The
reason for the con¯icting results is not known, neither as
study populations, nor differences in age of subjects or
follow-up time appear to explain this discrepancy.
Although it is supposed that even moderately increased
plasma tHcy concentrations are associated with an elevated
risk of vascular disease in the coronary, cerebral and
peripheral arteries, the risk-increasing mechanisms of
plasma tHcy are still poorly understood. Theoretically
folate is an important substrate in the remethylation of
homocysteine back to methionine. According to a recent
meta-analysis (Homocysteine Lowering Trialists' Colla-
boration, 1998), after standardization to pretreatment
blood concentrations of homocysteine of 12 mmol=l and
folate of 12 nmol=l (approximate average concentrations
for Western populations), supplemented folic acid reduced
blood homocysteine concentrations by 25%, with similar
effects in the range of 0.5 ± 5 mg folic acid daily. Although
folic acid could lower the risk of CHD through reducing
plasma homocysteine concentrations, homocysteine may
also be only a marker for folate and vitamin B6 status
rather than a causal risk factor. BrattstroÈm and co-workers
examined recently in their meta-analysis an association
between the common methylenetetrahydrofolate reductase
gene mutation, which causes hyperhomocysteinaemia, with
homocysteine concentrations, and the risk of vascular
diseases (BrattstroÈm et al, 1998). They concluded that,
although this gene mutation is a major cause of mild
hyperhomocysteinaemia, it does not increase cardiovascu-
lar risk. They concluded that mild hyperhomocysteinaemia
found frequently in vascular disease patients is not causally
related to the pathogenesis of the vascular disease.
The mean serum concentrations of the folate in our
study were similar to those reported previously in other
studies (Giles et al, 1995 1998). The mean daily dietary
intake of folic acid measured at the KIHD baseline was
227 mg=day, and mean daily intake more than the currently
recommended daily allowance (RDA) 300 mg=day was
observed for only 13% of the study subjects. Before
1986, the RDA for dietary folic acid was 400 mg=day, and
it was then changed to 180 mg=day for women and
200 mg=day for men and again in 1997 to 300 mg=day for
both men and women. We believe that the recently recom-
mended daily allowance of 400 mg=day could be bene®cial
for cardiovascular health.
Together with the previous ®ndings, our results support
the theory that folate has a role in the prevention of CHD.
Intervention studies are required to test the effect of folic
acid supplementation in cardiovascular health.
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